Improvement of aging-associated cardiovascular dysfunction by the orally administered copper(II)-aspirinate complex.
D000284:Administration, Oral; D000375:Aging / Q000187:drug effects* / Q000235:genetics / Q000473:pathology / Q000502:physiology*; D000818:Animals; D000975:Antioxidants / Q000008:administration & dosage; D001241:Aspirin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D001483:Base Sequence; D002319:Cardiovascular System / Q000187:drug effects* / Q000473:pathology / Q000503:physiopathology*; D051546:Cyclooxygenase 2 / Q000235:genetics; D017931:DNA Primers / Q000235:genetics; D004730:Endothelium, Vascular / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology; D066298:In Vitro Techniques; D052247:Nitric Oxide Synthase Type II / Q000235:genetics; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D051381:Rats; D011917:Rats, Inbred Lew
D000975:Antioxidants; D017931:DNA Primers; D012333:RNA, Messenger; C027058:tetrakis-mu-acetylsalicylato-dicopper(II); D052247:Nitric Oxide Synthase Type II; C496318:Nos2 protein, rat; D051546:Cyclooxygenase 2; C489691:Ptgs2 protein, rat; D001241:Aspirin